Eris Lifesciences reported strong Q3 FY26 results with consolidated revenue of ₹807.45 crore, up 11.00% YoY, and net profit of ₹108.83 crore. The company recorded exceptional items of ₹17.24 crore due to new labour codes implementation. For nine months FY26, revenue reached ₹2,372.86 crore with net profit of ₹368.40 crore, showing 34.94% growth. Post-quarter, the company acquired remaining 30% stake in Swiss Parenterals Limited, making it wholly-owned subsidiary.
Eris Lifesciences Reports Q3 FY26 Results with Revenue Growth of 11.00%
